Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer

Purpose: In a substantial population of non–small cell lung cancer (NSCLC), expression and activation of EGF receptor (EGFR) have been reported and is regarded as a novel molecular target. A growing body of evidence has shown the signaling crosstalk between EGFR and integrins in cellular migration and invasion. NEDD9 is an integrin signaling adaptor protein composed of multiple domains serving as substrate for a variety of tyrosine kinases. In the present study, we aimed at elucidating a role of NEDD9 in the signaling crosstalk between EGFR and integrins. Experimental Design: Using NSCLC cell lines, we conducted immunoblotting and cellular migration/invasion assay in vitro. Next, we analyzed metastasis assays in vivo by the use of xenograft transplantation model. Finally, we retrospectively evaluated clinical samples and records of patients with NSCLCs. Results: We showed that tyrosine phosphorylation of NEDD9 was reduced by the inhibition of EGFR in NSCLC cell lines. Overexpression of constitutively active EGFR caused tyrosine phosphorylation of NEDD9 in the absence of integrin stimulation. By gene transfer and gene knockdown, we showed that NEDD9 plays a pivotal role in cell migration and invasion of those cells in vitro. Furthermore, overexpression of NEDD9 promoted lung metastasis of an NSCLC cell line in NOD/Shi-scid, IL-2Rγnull mice (NOG) mice. Finally, univariate and multivariate Cox model analysis of NSCLC clinical specimens revealed a strong correlation between NEDD9 expression and recurrence-free survival as well as overall survival. Conclusion: Our data thus suggest that NEDD9 is a promising biomarker for the prognosis of NSCLCs and its expression can promote NSCLC metastasis. Clin Cancer Res; 18(22); 6326–38. ©2012 AACR.

[1]  M. Papotti,et al.  β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells , 2011, Oncogene.

[2]  Jasmin H. Bavarva,et al.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression , 2011, Oncogene.

[3]  Y. Loh,et al.  An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. , 2011, The Journal of clinical investigation.

[4]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[5]  J. Lucas,et al.  Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent , 2010, Oncogene.

[6]  Sun-Hee Kim,et al.  Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. , 2010, Cancer research.

[7]  V. Holla,et al.  HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. , 2010, Cancer Research.

[8]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[9]  A. Sihoe,et al.  Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy , 2009, Molecular Cancer Research.

[10]  P. Boyle,et al.  World Cancer Report 2008 , 2009 .

[11]  S. Hanks,et al.  Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. , 2009, Cancer research.

[12]  G. O'Neill,et al.  A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. , 2007, Cancer research.

[13]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[14]  E. Golemis,et al.  HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells , 2007, Oncogene.

[15]  F. Hirsch,et al.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[17]  L. Chin,et al.  Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene , 2006, Cell.

[18]  A. Sapino,et al.  p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. , 2006, Cancer research.

[19]  N. Saijo,et al.  Dimerization and the signal transduction pathway of a smallin‐frame deletion in the epidermal growth factor receptor , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Yusuke Inoue,et al.  In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[22]  S. Ogawa,et al.  Crk-Associated Substrate Lymphocyte Type Is Required for Lymphocyte Trafficking and Marginal Zone B Cell Maintenance1 , 2005, The Journal of Immunology.

[23]  R. Assoian,et al.  Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression , 2005, Cancer and Metastasis Reviews.

[24]  N. Saijo,et al.  Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib , 2005, International journal of cancer.

[25]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[26]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[27]  Arthur J. Olson,et al.  The Serine-rich Domain from Crk-associated Substrate (p130cas) Is a Four-helix Bundle* , 2005, Journal of Biological Chemistry.

[28]  S. Iwata,et al.  HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L) , 2005, Oncogene.

[29]  C. ffrench-Constant,et al.  Integrins: versatile integrators of extracellular signals. , 2004, Trends in cell biology.

[30]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[31]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[32]  Q. Ding,et al.  The Pattern of Enhancement of Src Kinase Activity on Platelet-derived Growth Factor Stimulation of Glioblastoma Cells Is Affected by the Integrin Engaged* , 2003, Journal of Biological Chemistry.

[33]  M. Hung,et al.  Dysregulation of cellular signaling by HER2/neu in breast cancer. , 2003, Seminars in oncology.

[34]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[35]  C. Tacchetti,et al.  Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines* , 2002, The Journal of Biological Chemistry.

[36]  Jung Weon Lee,et al.  The α5β1 integrin selectively enhances epidermal growth factor signaling to the phosphatidylinositol-3-kinase/Akt pathway in intestinal epithelial cells , 2002 .

[37]  R. Herbst,et al.  ZD1839 (Iressa) in non-small cell lung cancer. , 2001, The oncologist.

[38]  Jung Weon Lee,et al.  The alpha5beta1 integrin selectively enhances epidermal growth factor signaling to the phosphatidylinositol-3-kinase/Akt pathway in intestinal epithelial cells. , 2002, Biochimica et biophysica acta.

[39]  F. Khuri,et al.  ZD1839 (Iressa) in non-small-cell lung cancer. , 2002, Clinical lung cancer.

[40]  C. Arteaga.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Kanner,et al.  Focal adhesion kinase regulates β1 integrin‐dependent T cell migration through an HEF1 effector pathway , 2001, European journal of immunology.

[42]  S. Kanner,et al.  Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway. , 2001, European journal of immunology.

[43]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[44]  M. Einarson,et al.  The Docking Protein HEF1 Is an Apoptotic Mediator at Focal Adhesion Sites , 2000, Molecular and Cellular Biology.

[45]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[46]  S. van der Flier,et al.  BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. , 2000, Journal of the National Cancer Institute.

[47]  K. Kamiguchi,et al.  Tyrosine phosphorylation of Crk-associated substrate lymphocyte-type is a critical element in TCR- and beta 1 integrin-induced T lymphocyte migration. , 1999, Journal of immunology.

[48]  K. Kamiguchi,et al.  T Cell Receptor-mediated Tyrosine Phosphorylation of Cas-L, a 105-kDa Crk-associated Substrate-related Protein, and Its Association of Crk and C3G* , 1998, The Journal of Biological Chemistry.

[49]  N. Heisterkamp,et al.  BCR/ABL-induced Leukemogenesis Causes Phosphorylation of Hef1 and Its Association with Crkl* , 1997, The Journal of Biological Chemistry.

[50]  K. Kamiguchi,et al.  Tyrosine Phosphorylation of Crk-associated Substrates by Focal Adhesion Kinase , 1997, The Journal of Biological Chemistry.

[51]  S. Iwata,et al.  Structure and function of Cas-L, a 105-kD Crk-associated substrate- related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes , 1996, The Journal of experimental medicine.

[52]  E. Golemis,et al.  Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae , 1996, Molecular and cellular biology.

[53]  S. Ogawa,et al.  A novel signaling molecule, p130, forms stable complexes in vivo with v‐Crk and v‐Src in a tyrosine phosphorylation‐dependent manner. , 1994, The EMBO journal.

[54]  S. Kumar,et al.  Identification of a set of genes with developmentally down-regulated expression in the mouse brain. , 1992, Biochemical and biophysical research communications.

[55]  C. Morimoto,et al.  Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein , 1992, The Journal of experimental medicine.

[56]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[57]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.